203 related articles for article (PubMed ID: 38270915)
21. AIRE is expressed in breast cancer TANs and TAMs to regulate the extrinsic apoptotic pathway and inflammation.
Källberg E; Mehmeti-Ajradini M; Björk Gunnarsdottir F; Göransson M; Bergenfelz C; Allaoui Fredriksson R; Hagerling C; Johansson ME; Welinder C; Jirström K; Leandersson K
J Leukoc Biol; 2024 Mar; 115(4):664-678. PubMed ID: 38060995
[TBL] [Abstract][Full Text] [Related]
22. G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.
Martinez Sanz P; van Rees DJ; van Zogchel LMJ; Klein B; Bouti P; Olsman H; Schornagel K; Kok I; Sunak A; Leeuwenburg K; Timmerman I; Dierselhuis MP; Kholosy WM; Molenaar JJ; van Bruggen R; van den Berg TK; Kuijpers TW; Matlung HL; Tytgat GAM; Franke K
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049929
[TBL] [Abstract][Full Text] [Related]
23. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
[TBL] [Abstract][Full Text] [Related]
24. An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa
Kang TH; Lee CH; Delidakis G; Jung J; Richard-Le Goff O; Lee J; Kim JE; Charab W; Bruhns P; Georgiou G
Front Immunol; 2019; 10():562. PubMed ID: 30984171
[TBL] [Abstract][Full Text] [Related]
25. Role of low-affinity Fc receptors in antibody-dependent tumor cell phagocytosis by human monocyte-derived macrophages.
Munn DH; McBride M; Cheung NK
Cancer Res; 1991 Feb; 51(4):1117-23. PubMed ID: 1825476
[TBL] [Abstract][Full Text] [Related]
26. Tumor-associated macrophages promote invasion while retaining Fc-dependent anti-tumor function.
Grugan KD; McCabe FL; Kinder M; Greenplate AR; Harman BC; Ekert JE; van Rooijen N; Anderson GM; Nemeth JA; Strohl WR; Jordan RE; Brezski RJ
J Immunol; 2012 Dec; 189(11):5457-66. PubMed ID: 23105143
[TBL] [Abstract][Full Text] [Related]
27. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).
Ball ED; Guyre PM; Mills L; Fisher J; Dinces NB; Fanger MW
J Hematother; 1992; 1(1):85-94. PubMed ID: 1365020
[TBL] [Abstract][Full Text] [Related]
28. Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions.
Baumann N; Rösner T; Jansen JHM; Chan C; Marie Eichholz K; Klausz K; Winterberg D; Müller K; Humpe A; Burger R; Peipp M; Schewe DM; Kellner C; Leusen JHW; Valerius T
Cancer Sci; 2021 Aug; 112(8):3029-3040. PubMed ID: 34058788
[TBL] [Abstract][Full Text] [Related]
29. Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies.
Sioud M; Westby P; Vasovic V; Fløisand Y; Peng Q
FASEB J; 2018 Sep; 32(9):5063-5077. PubMed ID: 29913558
[TBL] [Abstract][Full Text] [Related]
30. Human alveolar macrophage FcR-mediated cytotoxicity. Heteroantibody- versus conventional antibody-mediated target cell lysis.
Levy PC; Looney RJ; Shen L; Graziano RF; Fanger MW; Roberts NJ; Ryan DH; Utell MJ
J Immunol; 1990 May; 144(10):3693-700. PubMed ID: 2332629
[TBL] [Abstract][Full Text] [Related]
31. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133
[TBL] [Abstract][Full Text] [Related]
32. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
Zhou SL; Zhou ZJ; Hu ZQ; Huang XW; Wang Z; Chen EB; Fan J; Cao Y; Dai Z; Zhou J
Gastroenterology; 2016 Jun; 150(7):1646-1658.e17. PubMed ID: 26924089
[TBL] [Abstract][Full Text] [Related]
33. FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils.
Treffers LW; van Houdt M; Bruggeman CW; Heineke MH; Zhao XW; van der Heijden J; Nagelkerke SQ; Verkuijlen PJJH; Geissler J; Lissenberg-Thunnissen S; Valerius T; Peipp M; Franke K; van Bruggen R; Kuijpers TW; van Egmond M; Vidarsson G; Matlung HL; van den Berg TK
Front Immunol; 2018; 9():3124. PubMed ID: 30761158
[TBL] [Abstract][Full Text] [Related]
34. Targeting FcαRI on polymorphonuclear cells induces tumor cell killing through autophagy.
Bakema JE; Ganzevles SH; Fluitsma DM; Schilham MW; Beelen RH; Valerius T; Lohse S; Glennie MJ; Medema JP; van Egmond M
J Immunol; 2011 Jul; 187(2):726-32. PubMed ID: 21653835
[TBL] [Abstract][Full Text] [Related]
35. Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils.
Behrens LM; van den Berg TK; van Egmond M
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884427
[TBL] [Abstract][Full Text] [Related]
36. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
37. Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis.
Vijayaraghavan S; Lipfert L; Chevalier K; Bushey BS; Henley B; Lenhart R; Sendecki J; Beqiri M; Millar HJ; Packman K; Lorenzi MV; Laquerre S; Moores SL
Mol Cancer Ther; 2020 Oct; 19(10):2044-2056. PubMed ID: 32747419
[TBL] [Abstract][Full Text] [Related]
38. Sodium stibogluconate and CD47-SIRPα blockade overcome resistance of anti-CD20-opsonized B cells to neutrophil killing.
van Rees DJ; Brinkhaus M; Klein B; Verkuijlen P; Tool ATJ; Schornagel K; Treffers LW; van Houdt M; Kater AP; Vidarsson G; Gennery AR; Kuijpers TW; van Bruggen R; Matlung HL; van den Berg TK
Blood Adv; 2022 Apr; 6(7):2156-2166. PubMed ID: 34942000
[TBL] [Abstract][Full Text] [Related]
39. A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.
Guettinger Y; Barbin K; Peipp M; Bruenke J; Dechant M; Horner H; Thierschmidt D; Valerius T; Repp R; Fey GH; Stockmeyer B
J Immunol; 2010 Feb; 184(3):1210-7. PubMed ID: 20042573
[TBL] [Abstract][Full Text] [Related]
40. Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function.
La Fleur L; Botling J; He F; Pelicano C; Zhou C; He C; Palano G; Mezheyeuski A; Micke P; Ravetch JV; Karlsson MCI; Sarhan D
Cancer Res; 2021 Feb; 81(4):956-967. PubMed ID: 33293426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
